臺灣學術機構典藏系統 (Taiwan Academic Institutional Repository, TAIR)

	English \| 正體中文 \| 简体中文 \| 总笔数 :0
	造访人次 : 51889297 在线人数 : 892 教育部委托研究计画计画执行:国立台湾大学图书馆

搜寻范围

进阶搜寻

登入

管理

臺灣學術機構典藏系統 (Taiwan Academic Institutional Repository, TAIR)

关于TAIR
	计画说明

浏览
	典藏机构
	作者
	题名
	日期
	统计图表
	机构即时统计
	学术趋势

消息
	2019臺灣學術機構典藏研討會
	機構典藏系統RC7版本已發佈

著作权
	出版社及期刊政策查询
	TAIR著作权会议记录

相关连结
	機構典藏計畫網站
	ROAR
	OpenDOAR
	SHERPA
	OAIster
	JAIRO
	Ira
	DSPACE
	RWWR
	臺大學術典藏NTU Scholars

"zhong zhe lin"的相关文件

回到依作者浏览
依题名排序	依日期排序

显示项目 41-50 / 125 (共13页)
<< < 1 2 3 4 5 6 7 8 9 10 > >>
每页显示[10|25|50]项目

机构	日期	题名	作者
臺大學術典藏	2022-06-10T06:11:02Z	Statin Use Is Associated With Improved Prognosis of Colorectal Cancer in Taiwan	Shao Y.-Y.; Hsu C.-H.; Yeh K.-H.; Chen H.-M.; Yeh Y.-C.; Lai C.-L.; ZHONG-ZHE LIN; Cheng A.-L.; Lai M.-S.
臺大學術典藏	2022-06-10T06:11:01Z	The response, outcome and toxicity of aggressive palliative thoracic radiotherapy for metastatic non-small cell lung cancer patients with controlled extrathoracic diseases	Chiang Y.; Yang J.C.-H.; Hsu F.-M.; Chen Y.-H.; Shih J.-Y.; ZHONG-ZHE LIN; Lan K.-H.; Cheng A.-L.; Kuo S.-H.
臺大學術典藏	2022-06-10T06:11:00Z	Primary tumor site is a useful predictor of cetuximab efficacy in the third-line or salvage treatment of KRAS wild-type (exon 2 non-mutant) metastatic colorectal cancer: A nationwide cohort study	Chen K.-H.; Shao Y.-Y.; Chen H.-M.; Lin Y.-L.; ZHONG-ZHE LIN; Lai M.-S.; Cheng A.-L.; Yeh K.-H.
臺大學術典藏	2022-06-10T06:11:00Z	Real-world data on prognostic factors for overall survival in EGFR mutation-positive advanced non-small cell lung cancer patients treated with first-line gefitinib	Yao Z.-H.; Liao W.-Y.; Ho C.-C.; Chen K.-Y.; Shih J.-Y.; Chen J.-S.; ZHONG-ZHE LIN; Lin C.-C.; Yang J.C.H.; Yu C.-J.
臺大學術典藏	2022-06-10T06:11:00Z	Phase Ib study of codrituzumab in combination with sorafenib in patients with non-curable advanced hepatocellular carcinoma (HCC)	Abou-Alfa G.K.; Yen C.-J.; Hsu C.-H.; O��Donoghue J.; Beylergil V.; Ruan S.; Pandit-Taskar N.; Gansukh B.; Lyashchenko S.K.; Ma J.; Wan P.; Shao Y.-Y.; ZHONG-ZHE LIN; Frenette C.; O��Neil B.; Schwartz L.; Smith-Jones P.M.; Ohtomo T.; Tanaka T.; Morikawa H.; Maki Y.; Ohishi N.; Chen Y.-C.; Agajanov T.; Boisserie F.; Di Laurenzio L.; Lee R.; Larson S.M.; Cheng A.-L.; Carrasquilo J.A.
臺大學術典藏	2022-06-10T06:10:59Z	A phase II study of the efficacy and safety of the MET inhibitor capmatinib (INC280) in patients with advanced hepatocellular carcinoma	Qin S.; Chan S.L.; Sukeepaisarnjaroen W.; Han G.; Choo S.P.; Sriuranpong V.; Pan H.; Yau T.; Guo Y.; Chen M.; Ren Z.; Xu J.; Yen C.-J.; ZHONG-ZHE LIN; Manenti L.; Gu Y.; Sun Y.; Tiedt R.; Hao L.; Song W.; Tanwandee T.
臺大學術典藏	2022-06-10T06:10:59Z	Lenalidomide as second-line therapy for advanced hepatocellular carcinoma: exploration of biomarkers for treatment efficacy	Shao Y.-Y.; Chen B.-B.; Ou D.-L.; ZHONG-ZHE LIN; Hsu C.-H.; Wang M.-J.; Cheng A.-L.; Hsu C.
臺大學術典藏	2022-06-10T06:10:58Z	Considerations of heterogeneity in clinical trials for hepatocellular carcinoma	Liu T.-H.; Shao Y.-Y.; Lu L.-C.; Shen Y.-C.; Hsu C.; ZHONG-ZHE LIN; Hsu C.-H.; Cheng A.-L.
臺大學術典藏	2022-06-10T06:10:58Z	Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations	Lin Y.-T.; Chen J.-S.; Liao W.-Y.; Ho C.-C.; Hsu C.-L.; Yang C.-Y.; Chen K.-Y.; Lee J.-H.; ZHONG-ZHE LIN; Shih J.-Y.; Yang J.C.-H.; Yu C.-J.
臺大學術典藏	2022-06-10T06:10:57Z	Development and validation of nomograms for predicting survival probability of patients with advanced adenocarcinoma in different EGFR mutation status	Chen H.-C.; Tan E.C.-H.; Liao C.-H.; ZHONG-ZHE LIN; Yang M.-C.

显示项目 41-50 / 125 (共13页)
<< < 1 2 3 4 5 6 7 8 9 10 > >>
每页显示[10|25|50]项目